Monday, December 12, 2005

Myogen Announces Positive Phase III Results

Myogen announced today that Ambrisentan®, for pulmonary arterial hypertension, met the primary efficacy endpoint and several strategic secondary endpoints in this first Phase III trial. Results are expected shortly, in 1Q06, on an additional Phase III study. To date Ambrisentan® has demonstrated:

• Improvement in exercise capacity
• Improvement in time to clinical worsening
• An apparent survival benefit when compared with predicted survival based on the NIH
Registry formula
• Effectiveness with once-daily dosing and the potential for dose flexibility
• Low incidence and severity of liver function test abnormalities at all doses
• No apparent drug-drug interactions with warfarin-type anticoagulants

Wall St. is certainly responding favorably to the announced results as well as the share price has jumped nearly 68%, up 9.33 to $28.05 over Friday’s close of $19.27. Here is a link to today’s web cast if you are interested in hearing more.

No comments: